Related Experiment Video

Updated: Nov 4, 2025

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K

TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery

Shuang Xiang1, Shukai Song1, Haotian Tang2

  • 1Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China.

Drug Discovery Today
|May 29, 2021
PubMed

Insights

TANK-binding kinase 1 (TBK1) dysregulation drives diseases like inflammation and cancer. This review explores TBK1

Area of Science:

  • Molecular Biology
  • Immunology
  • Oncology
  • Pharmacology

Background:

  • TANK-binding kinase 1 (TBK1) plays a crucial role in cellular signaling pathways.
  • Homeostatic imbalance of TBK1 is implicated in various pathologies, including inflammatory, autoimmune, metabolic disorders, and cancer.
  • Targeting TBK1 presents a therapeutic opportunity for diverse disease conditions.

Purpose of the Study:

  • To elucidate the multifaceted biological functions of TBK1.
  • To review and summarize emerging small-molecule inhibitors targeting TBK1.
  • To identify potential therapeutic candidates for disease treatment.

Main Methods:

  • Comprehensive literature review of TBK1's biological roles.
  • Systematic search and analysis of published small-molecule TBK1 inhibitors.
  • Evaluation of inhibitor properties and therapeutic potential.

Main Results:

  • TBK1 is involved in key pathways regulating immunity, inflammation, and cell survival.
  • Several small-molecule inhibitors targeting TBK1 have demonstrated promising preclinical activity.
  • These inhibitors exhibit diverse mechanisms of action and chemical scaffolds.

Conclusions:

  • TBK1 is a critical therapeutic target for a range of diseases.
  • The development of small-molecule TBK1 inhibitors is advancing rapidly.
  • Further research into these inhibitors holds significant promise for novel therapeutic strategies.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.3K
Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein11:23

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Published on: June 30, 2019

6.4K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.3K
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.3K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
14.0K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.7K